Evidence map›Paper›PMID 41065843›Full record

ArticleCancer immunology, immunotherapy : CII2025

Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDAC.

Anastasia Xagara, Konstantina Vasilieva, Alexandros Kokkalis, Alexandros Lazarou, George Christodoulopoulos, Vasileios Papadopoulos, Evangelia Chantzara, Fillipos Koinis, Emmanouil Saloustros, Galatea Kallergi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anastasia XagaraLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110, Larissa, Greece.
Konstantina VasilievaLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110, Larissa, Greece.
Alexandros KokkalisDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Alexandros LazarouDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
George ChristodoulopoulosDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Vasileios PapadopoulosDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Evangelia ChantzaraDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Fillipos KoinisDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Emmanouil SaloustrosDepartment of Medical Oncology, University General Hospital of Larissa, 41110, Larissa, Greece.
Galatea KallergiLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504, Patras, Greece.
Vassilis GeorgouliasHellenic Oncology Research Group (HORG), Gregoriou Theologou 5, 11474, Athens, Greece.
Ioannis S Pateras2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Athanasios KotsakisLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110, Larissa, Greece. thankotsakis@uth.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is a lethal malignancy with few treatment options. Despite the promising results of immunotherapy in various solid cancers, the efficacy of immunotherapy in PDAC is poor. Therefore, deciphering immune responses is pivotal for the development of novel combinatorial immunotherapies. Here, we analyzed the immunophenotypic profile of circulating distinct T-cell subtypes and their prognostic value in early and advanced/metastatic PDAC patients by using multicolor flow-cytometry. We observed higher percentages of progenitor exhausted TCF1

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsT-LymphocytesAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorBiomarkers, TumorProgrammed Cell Death 1 ReceptorPD-1PDACT-cell exhaustionTCF1

Identifiers

PMID41065843
PMCPMC12511512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.